Somatuline Depot (lanreotide) — Medica
Neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, thymus (carcinoid tumors), and pancreas (including glucagonomas, gastrinomas, VIPomas, insulinomas)
Initial criteria
- Medication is prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist
Reauthorization criteria
- Prescriber continues to be an oncologist, endocrinologist, or gastroenterologist
- Continued need for treatment as determined by clinical assessment
Approval duration
1 year